NASDAQ:MYLMylan Stock Price, Forecast & News

$17.67

+0.19 (+1.09 %)

(As of 06/3/2020 11:45 AM ET)

Add

Compare

Today's Range

$17.49

Now: $17.67▼

$17.75

50-Day Range

$14.91

MA: $16.22▼

$17.62

52-Week Range

$12.75

Now: $17.67▼

$23.11

Volume983,216 shs

Average Volume6.90 million shs

Market Capitalization$9.13 billion

P/E Ratio147.26

Dividend YieldN/A

Beta1.54

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Beat the Market (BTM) Rank^™

4.3 Analyst's Opinion

Consensus Rating
Mylan has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $23.46, Mylan has a potential upside of 32.8% from its current price of $17.67.
Amount of Analyst Coverage
Mylan has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Mylan has received 751 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Mylan has received 623 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Mylan has received 54.66% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote “Outperform” if you believe MYL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Mylan does not currently pay a dividend.
Dividend Growth
Mylan does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mylan insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.82% of the stock of Mylan is held by insiders.
Percentage Held by Institutions
85.52% of the stock of Mylan is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Mylan are expected to grow by 2.30% in the coming year, from $4.34 to $4.44 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mylan is 147.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.96.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mylan is 147.26, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.43.
Price to Earnings Growth Ratio
Mylan has a PEG Ratio of 1.87. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Mylan has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.84 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:MYL

Previous Symbol

CUSIP62853010

CIK1623613

Webwww.mylan.com

Phone724-514-1800

Debt

Debt-to-Equity Ratio1.08

Current Ratio1.26

Quick Ratio0.76

Price-To-Earnings

Trailing P/E Ratio147.26

Forward P/E Ratio4.07

P/E Growth1.87

Sales & Book Value

Annual Sales$11.50 billion

Price / Sales0.79

Cash Flow$8.33 per share

Price / Cash Flow2.12

Book Value$23.02 per share

Price / Book0.77

Profitability

EPS (Most Recent Fiscal Year)$4.42

Net Income$16.80 million

Net Margins0.54%

Return on Equity20.00%

Return on Assets7.49%

Miscellaneous

Employees35,000

Outstanding Shares516,940,000

Market Cap$9.13 billion

Next Earnings Date8/3/2020 (Estimated)

OptionableOptionable

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Mylan (NASDAQ:MYL) Frequently Asked Questions

How has Mylan's stock been impacted by COVID-19 (Coronavirus)?

Mylan's stock was trading at $14.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYL stock has increased by 22.1% and is now trading at $17.67. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mylan?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mylan.

When is Mylan's next earnings date?

Mylan is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mylan.

How were Mylan's earnings last quarter?

Mylan NV (NASDAQ:MYL) released its earnings results on Monday, May, 11th. The company reported $0.90 EPS for the quarter, topping the Zacks' consensus estimate of $0.86 by $0.04. The firm earned $2.62 billion during the quarter, compared to analysts' expectations of $2.65 billion. Mylan had a net margin of 0.54% and a return on equity of 20.00%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.82 EPS. View Mylan's earnings history.

What guidance has Mylan issued on next quarter's earnings?

Mylan issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.74 billion.

What price target have analysts set for MYL?

14 equities research analysts have issued 12 month price objectives for Mylan's shares. Their forecasts range from $17.00 to $34.50. On average, they anticipate Mylan's stock price to reach $23.46 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price. View analysts' price targets for Mylan.

Has Mylan been receiving favorable news coverage?

Headlines about MYL stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mylan earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View the latest news aboutMylan.

Who are some of Mylan's key competitors?

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Zogenix (ZGNX) and Corcept Therapeutics (CORT). View all competitors.

What other stocks do shareholders of Mylan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (gild), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Starbucks (SBUX), Intel (INTC), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Mylan's key executives?

Mylan's management team includes the following people:

Ms. Heather Bresch, CEO & Exec. Director (Age 50)
Mr. Rajiv Malik, Pres & Exec. Director (Age 58)
Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)
Mr. Anthony Mauro, Chief Commercial Officer (Age 46)
Mr. Daniel M. Gallagher Jr., Advisor (Age 46)

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Who are Mylan's major shareholders?

Mylan's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (11.00%), State Street Corp (4.48%), Pzena Investment Management LLC (3.79%), AQR Capital Management LLC (2.20%), Geode Capital Management LLC (1.93%) and Invesco Ltd. (1.72%). Company insiders that own Mylan stock include Goulds Bruce, Melina E Higgins, Paul Campbell, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View institutional ownership trends for Mylan.

Which major investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Camber Capital Management LP, Nuveen Asset Management LLC, Pzena Investment Management LLC, Morgan Stanley, Morgan Stanley, Magnetar Financial LLC, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Mylan.

Which major investors are buying Mylan stock?

MYL stock was acquired by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Iridian Asset Management LLC CT, Wellington Management Group LLP, AQR Capital Management LLC, First Manhattan Co., Retirement Systems of Alabama, AXA, and Acadian Asset Management LLC. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury, and Sjoerd S Vollebregt. View insider buying and selling activity for Mylan.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $17.67.

How big of a company is Mylan?

Mylan has a market capitalization of $9.13 billion and generates $11.50 billion in revenue each year. The company earns $16.80 million in net income (profit) each year or $4.42 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

What is Mylan's official website?

The official website for Mylan is www.mylan.com.

How can I contact Mylan?

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff